NCT02909023View on ClinicalTrials.gov

Performance of the HBV ELISPOT in the Detection of the T Cellular Immune Response in Patients Infected by HBV or Cured

CompletedOBSERVATIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

November 30, 2016

Conditions
Hepatitis B
Interventions
BIOLOGICAL

blood samples are performed to measure active T cellular immune response during a routine visit

"During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV.~The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit."

Trial Locations (1)

69004

Hôpital de la Croix Rousse, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT02909023 - Performance of the HBV ELISPOT in the Detection of the T Cellular Immune Response in Patients Infected by HBV or Cured | Biotech Hunter | Biotech Hunter